Aida Home Design Philippines Inc

What Aida Home Design Philippines Inc does

MSD Philippines (Merck Sharp & Dohme) is the Philippine operating entity of Merck & Co., Inc. (NYSE: MRK), a research-intensive biopharmaceutical company established in the Philippines in 1995. The company offers innovative prescription medicines, vaccines, biologic therapies, and animal health products across four therapeutic focus areas: Oncology, Vaccines, Infectious Diseases, and Diabetes. Its portfolio includes HPV and pneumococcal vaccines, HIV treatments, Ebola countermeasures, and investigational compounds such as molnupiravir, which was clinically trialed in the Philippines in 2023.

The business operates through a multi-channel go-to-market model combining direct hospital and clinic sales via medical representatives, retail pharmacy partnerships (Mercury Drug, SouthStar Drug), government procurement through the Department of Health (national immunization, school-based HPV vaccination, NICCA cancer control), and specialty diagnostics collaborators (Hi-Precision, Detoxicare). Revenue is generated through one-time vaccine sales, recurring prescription medicine and biologic therapy sales, and animal health product distribution. The company also invests heavily in advocacy and patient education through campaigns including Hope From Within (reaching 20M+ Filipinos), Bakuna Muna, Call the Shots, Guard Against HPV, and the Kontrolado Ko Diabetes Ko program.

MSD Philippines is part of a globally significant parent that invested $13.6B in R&D in 2020 and employs 16,700 R&D personnel; locally it operates with partnerships spanning medical societies, patient coalitions, and government stakeholders. The 2025 launch of the AI-powered 'Let's Talk Lung' chatbot signals an emerging digital patient engagement layer atop the pharmaceutical core. The entity does not disclose local revenue or full headcount, and operates under the legal name Merck Sharp & Dohme (I.A.) LLC — Philippines Branch.

Name

Aida Home Design Philippines Inc

Legal name

Merck Sharp & Dohme (I.A.) LLC

Website

https://msd.com.ph

Company type

Public

Founded year

1995

Operating status

Operating

Headcount range

1–10 employees

Short description

MSD Philippines, a subsidiary of Merck & Co. (NYSE: MRK), is a research-intensive biopharmaceutical company operating in the Philippines since 1995, distributing prescription medicines, vaccines, biologics, and animal health products across oncology, vaccines, infectious diseases, and diabetes to hospitals, pharmacies, and government health programs.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release) (HLAAAEAK)

akta.pro secondary industries

Global Health Research, Clinical Trials & Product Development Partnerships (PDPs) (HLAJAOAM), Vaccine Manufacturing & Contract Services (Veterinary Vaccine CDMO) (HLAMAKAI)

Keywords

• Prescription pharmaceuticals
• Vaccines development
• Oncology treatments
• Biologic therapies
• Animal health products

Headquarters

HQ city

Makati City

HQ country

Philippines

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain

Revenue model

1. Prescription Medicines: Sale of innovative prescription medicines for oncology, infectious diseases, diabetes, and other therapeutic areas through healthcare providers and pharmacies
2. Vaccines: Distribution of vaccines for prevention of infectious diseases including HPV, pneumonia, and other vaccine-preventable diseases through government programs, hospitals, and pharmacies
3. Biologic Therapies: Advanced biologic therapies for cancer treatment and other serious diseases
4. Animal Health Products: Animal health products through MSD Animal Health division

Go-to-market motion3 records

Distribution channels5 records

Core offering

MSD Philippines is a research-intensive biopharmaceutical company that develops, manufactures, and distributes innovative prescription medicines, vaccines, biologic therapies, and animal health products across four core therapeutic areas: oncology, infectious diseases, vaccines, and diabetes. The company operates as the Philippines branch of Merck Sharp & Dohme (I.A.) LLC and serves the Philippine market with a portfolio spanning immuno-oncology, HIV treatment, HPV and pneumococcal vaccines, Ebola therapeutics, and chronic disease medications.

Product overview

MSD Philippines (Merck Sharp & Dohme) is a premier, research-intensive biopharmaceutical company that offers a portfolio of innovative prescription medicines, vaccines, biologic therapies, and animal health products. The company operates across four therapeutic focus areas: Oncology (delivering breakthrough innovations for cancer treatment including immunotherapy), Vaccines (discovering, developing, and delivering vaccines for over 100 years), Infectious Diseases (including HIV, Ebola, and antibiotics), and Diabetes (with patient support programs). MSD Philippines also runs multiple advocacy programs including Hope From Within (cancer awareness reaching 20M+ Filipinos), Bakuna Muna, Call the Shots, and Guard Against HPV. The company invested $13.6B in R&D in 2020 with 16.7K people in R&D roles.

Differentiator

Problem solved

Functional benefit

Brands

• Hope From Within: Multi-stakeholder cancer advocacy campaign launched in 2015, focused on cancer awareness, access, and patient safety for Filipino patients.
• Bakuna Muna
• Call the Shots
• Guard Against HPV
• Kontrolado Ko, Diabetes Ko (KKDK)
• MSD Gives Back
• Richard T. Clark (RTC) Fellowship for Global Health

Products and services

• Innovative Prescription Medicines A broad portfolio of innovative prescription pharmaceutical products spanning oncology, infectious diseases, vaccines, and diabetes, sold to hospitals, clinics, and pharmacies in the Philippines for the treatment of serious and chronic conditions.
• Vaccines Portfolio Vaccines for the prevention of infectious diseases including HPV and pneumococcal disease, distributed to healthcare providers, hospitals, and through government immunization programs in the Philippines.
• Oncology Medicines (Keytruda and immuno-oncology portfolio) Immuno-oncology and oncology medicines used for the treatment of multiple cancer types, prescribed by oncologists and administered in specialty cancer centers and hospitals in the Philippines.
• HIV Medicines Antiretroviral therapies for the treatment and prevention of HIV, supplied to specialized HIV treatment centers and clinics across the Philippines.
• Biologic Therapies Biologic therapy products developed through MSD's proprietary manufacturing platforms, used for specialty indications across oncology and other therapeutic areas and sold to institutional healthcare providers in the Philippines.
• Animal Health Products Animal health products for veterinary use, including companion animal and livestock health offerings, distributed in the Philippines.
• Molnupiravir (investigational oral antiviral) Investigational oral antiviral therapy for infectious disease indications being studied by MSD and Ridgeback Biotherapeutics and referenced on the MSD Philippines website.
• Ebola Therapeutic (EBV-Treatment) Therapeutic for Ebola virus disease referenced as part of MSD's infectious disease portfolio.
• Diabetes Medicines Prescription medicines for the treatment of diabetes, prescribed by endocrinologists and primary care physicians and dispensed through hospitals and retail pharmacies in the Philippines.

Quantifiable outcome

• HPV vaccine can reduce cervical cancer incidence by up to 90%
• +3 more outcomes

Named customers15 records

Ideal customer profiles2 records

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature6 records

Partnerships

22 partnerships are on record, tiered core and minor.

• American Chamber of Commerce (AmCham) PhilippinescoreGTM or Marketing Partner · 27 June 2025MSD Philippines participated in and received Bronze award in AmCham's inaugural Corporate Social Impact Awards recognizing community impact through employee-driven advocacy programs including EBRGs, MSD Gives Back, and RTC Fellowship.
• Philippine Foundation for Vaccination (PFV)coreStrategic or Co-development Partner · 24 April 2025MSD received Special Recognition Award from PFV during its 25th anniversary for contributions to vaccine research, development, safety monitoring, and public health. PFV is a key partner in promoting vaccine awareness in the Philippines.
• Philippine Foundation for Vaccination, Inc. (PFV)coreStrategic or Co-development Partner · 1 June 2023Staunch supporter of annual PNIC conference. Collaborated on 23rd Philippine National Immunization Congress with theme 'Leaving the Pandemic: Accelerating the Vaccine initiative, Vaccination Practices in the New Normal'.
• Philippine Pediatric Society - Southern Tagalog Chapter (PPS-STC)minorStrategic or Co-development Partner · 1 June 2023Co-organizer of 23rd Philippine National Immunization Congress.
• Mercury Drug CorporationcoreChannel Partner/ Reseller/ DistributorPartnership for 'Get Well at Mercury Drug - Diabetes Care' specialty corners providing diabetes care education and immunization awareness. Over 18 branches participating including locations in Metro Manila and provincial areas.
• Philippine Society of Endocrinology, Diabetes and Metabolism (PSEDM)minorStrategic or Co-development PartnerMedical society partner for diabetes care education programs, lectures on diabetes management and vaccination importance for diabetic patients.
• Philippine Pharmacists Association (PPhA)coreChannel Partner/ Reseller/ DistributorPartnership for pharmacy-based immunization programs and pharmacist training/certification for adult immunization. Approximately 1,000 trained immunizing pharmacists nationwide.
• Asian Hospital and Medical CentercoreStrategic or Co-development PartnerClinical trial site for molnupiravir COVID-19 prevention study. Recruited adult participants (18+) for post-exposure prophylaxis trial.
• Quirino Memorial Medical CentercoreStrategic or Co-development PartnerClinical trial site for molnupiravir COVID-19 prevention study. Partnered for Phase 3 trial recruiting close contacts of COVID-19 patients.
• Hi-Precision DiagnosticscoreStrategic or Co-development PartnerLaunch partner for 'Hit the Mark' precision medicine campaign providing lung cancer biomarker testing (EGFR, PD-L1) through unified patient form.
• Detoxicare Molecular Diagnostics LaboratorycoreStrategic or Co-development PartnerNewest partner in 'Hit the Mark' campaign expanding lung cancer biomarker testing access for eligible patients.
• Department of Health PhilippinescoreChannel Partner/ Reseller/ DistributorGovernment partner for national immunization programs, HPV vaccination under School-Based Immunization Program, and cancer control initiatives under NICCA.
• Jhpiego PhilippinescoreStrategic or Co-development PartnerPartner in SUCCESS (Scale Up Cervical Cancer Elimination with Secondary Prevention Strategy) project introducing HPV DNA testing and treatment of pre-cancerous lesions.
• Cancer Coalition PhilippinescoreStrategic or Co-development PartnerPatient advocacy coalition partner for cancer awareness, policy advocacy for NICCA implementation, and cervical cancer elimination efforts.
• Philippine Obstetrical and Gynecological Society (POGS)coreStrategic or Co-development PartnerMedical society partner for cervical cancer prevention, HPV vaccination advocacy, and women's cancer awareness campaigns.
• Philippine General HospitalminorStrategic or Co-development PartnerPartner for cervical cancer awareness events and patient education initiatives.
• MSD-Wellcome Trust Hilleman LaboratoriescoreStrategic or Co-development PartnerFirst-of-its-kind non-profit R&D joint venture focused on creating new vaccines and adapting existing vaccines for low-income countries, inspired by Dr. Maurice Hilleman's legacy.
• MaxicareminorChannel Partner/ Reseller/ DistributorHealthcare partner supporting 'Di Mo DeCerv' cervical cancer awareness event.
• Makati Medical CenterminorStrategic or Co-development PartnerPartner for cervical cancer awareness event pharmacy services promotion.
• CerviQminorStrategic or Co-development PartnerPartner organization for 'Di Mo DeCerv' cervical cancer awareness event.
• VaxcenminorChannel Partner/ Reseller/ DistributorPartner for 'Di Mo DeCerv' event promoting HPV vaccination awareness.
• UP National Institutes of HealthminorStrategic or Co-development PartnerProvided mathematical modeling for cervical cancer elimination timeline projections showing Philippines may achieve elimination between 2071-2098 without intervention.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Eli Lilly: Diabetes and oncology competitor; directly overlaps with MSD Philippines' diabetes franchise (where MSD runs KKDK) and increasingly in oncology as Lilly's pipeline matures.
• Bristol-Myers Squibb: Immuno-oncology leader that competes with MSD Philippines' Keytruda-class oncology portfolio in Philippine hospital channels and lung cancer indications.
• GSK: Major vaccines and specialty pharmaceuticals competitor with strong Philippines presence; directly competes with MSD Philippines in HPV, pneumococcal, and pediatric vaccines as well as HIV treatments.
• Novartis: Oncology and specialty pharma peer competing with MSD Philippines in targeted cancer therapies and chronic disease management across hospital and specialty pharmacy channels.
• Sanofi: Global vaccines and diabetes competitor; overlaps with MSD Philippines across the full vaccine portfolio and the diabetes franchise where MSD's KKDK program operates.
• AstraZeneca: Oncology and vaccines competitor with strong Philippines operations; directly contests MSD Philippines in lung cancer, immuno-oncology, and government immunization tenders.
• Pfizer: Global biopharmaceutical competitor with overlapping vaccines (including COVID-19), oncology, and infectious disease portfolios that competes head-to-head with MSD Philippines for government tenders, hospital sales, and retail pharmacy shelf space.
• Roche: Oncology and diagnostics leader; competes with MSD Philippines in lung cancer therapeutics and biomarker-driven personalized medicine, including the precision medicine space MSD is building through 'Hit the Mark'.
• Johnson & Johnson: Diversified pharma and vaccines competitor with overlapping oncology, infectious disease, and vaccine franchises; competes with MSD Philippines in hospital channels and government immunization programs.

Broad incumbents

• Abbott: Broader healthcare incumbent with significant Philippines presence across diagnostics, medical devices, nutrition, and established pharmaceuticals; competes indirectly with MSD Philippines in diabetes diagnostics, hospital supply, and consumer health adjacencies.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/msdinvents
• YouTubeyoutube.com/channel/UCAvkV8fXwmREOCE5xMX_Ddg
• Facebookfacebook.com/MSDInvents
• LinkedInlinkedin.com/company/aida-home-design-philippines-inc
• Instagraminstagram.com/msdinvents

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aida Home Design Philippines Inc